BioCentury | Mar 9, 2015
Strategy

Persevering with ProstVac

...mechanisms of immune system responses to cancer were understood (see "ProstVac in Time," page 8). Therion Biologics Corp....
...antigen. James Breitmeyer, EVP and president of cancer immunotherapy at Bavarian Nordic, said early on Therion...
...Bavarian Nordic licensed the candidate from NCI after its original developer, Therion Biologics Corp. , went bankrupt. Therion...
BioCentury | May 5, 2014
Clinical News

CV-301: Phase II started

...including bladder cancer, from the NCI, which regained rights to CV-301 after the previous licensee, Therion Biologics Corp....
BioCentury | Jun 17, 2013
Clinical News

CV-301: Phase II data

...from the National Cancer Institute (NCI), which regained rights to CV-301 after the previous licensee, Therion Biologics Corp....
BioCentury | Apr 15, 2013
Company News

Therion other research news

...that is active in multiple parts of the world where different HIV clades are prevalent. Therion Biologics Corp....
BioCentury | Oct 8, 2012
Clinical News

CV-301: Preliminary Phase II data

...treat certain cancers from the NCI, which regained rights to CV-301 after the previous licensee, Therion Biologics Corp....
BioCentury | Oct 2, 2012
Clinical News

Bavarian Nordic reports preliminary CV-301 data

...treat certain cancers from the NCI, which regained rights to CV-301 after the previous licensee, Therion Biologics Corp....
BioCentury | Dec 12, 2011
Clinical News

CV-301: Pilot trial data

...treat certain cancers from the NCI, which regained rights to CV-301 after the previous licensee, Therion Biologics Corp....
BioCentury | Oct 10, 2011
Company News

Bavarian Nordic deal

...cancer, with data expected in 1H12. NCI regained rights to CVAC-301 after the previous licensee, Therion Biologics Corp....
BioCentury | May 10, 2010
Clinical News

ProstVac regulatory update

...National Cancer Institute. Rights to ProstVac reverted back to the institute after the previous licensee, Therion Biologics Corp....
BioCentury | May 3, 2010
Product Development

Building on Provenge

...being developed under a CRADA with Bavarian Nordic A/S , was originally in development at Therion Biologics Corp....
...to it," noted Thomas Schuetz, an entrepreneur-in-residence at OrbiMed Advisors, who was previously CSO at Therion...
Items per page:
1 - 10 of 110
BioCentury | Mar 9, 2015
Strategy

Persevering with ProstVac

...mechanisms of immune system responses to cancer were understood (see "ProstVac in Time," page 8). Therion Biologics Corp....
...antigen. James Breitmeyer, EVP and president of cancer immunotherapy at Bavarian Nordic, said early on Therion...
...Bavarian Nordic licensed the candidate from NCI after its original developer, Therion Biologics Corp. , went bankrupt. Therion...
BioCentury | May 5, 2014
Clinical News

CV-301: Phase II started

...including bladder cancer, from the NCI, which regained rights to CV-301 after the previous licensee, Therion Biologics Corp....
BioCentury | Jun 17, 2013
Clinical News

CV-301: Phase II data

...from the National Cancer Institute (NCI), which regained rights to CV-301 after the previous licensee, Therion Biologics Corp....
BioCentury | Apr 15, 2013
Company News

Therion other research news

...that is active in multiple parts of the world where different HIV clades are prevalent. Therion Biologics Corp....
BioCentury | Oct 8, 2012
Clinical News

CV-301: Preliminary Phase II data

...treat certain cancers from the NCI, which regained rights to CV-301 after the previous licensee, Therion Biologics Corp....
BioCentury | Oct 2, 2012
Clinical News

Bavarian Nordic reports preliminary CV-301 data

...treat certain cancers from the NCI, which regained rights to CV-301 after the previous licensee, Therion Biologics Corp....
BioCentury | Dec 12, 2011
Clinical News

CV-301: Pilot trial data

...treat certain cancers from the NCI, which regained rights to CV-301 after the previous licensee, Therion Biologics Corp....
BioCentury | Oct 10, 2011
Company News

Bavarian Nordic deal

...cancer, with data expected in 1H12. NCI regained rights to CVAC-301 after the previous licensee, Therion Biologics Corp....
BioCentury | May 10, 2010
Clinical News

ProstVac regulatory update

...National Cancer Institute. Rights to ProstVac reverted back to the institute after the previous licensee, Therion Biologics Corp....
BioCentury | May 3, 2010
Product Development

Building on Provenge

...being developed under a CRADA with Bavarian Nordic A/S , was originally in development at Therion Biologics Corp....
...to it," noted Thomas Schuetz, an entrepreneur-in-residence at OrbiMed Advisors, who was previously CSO at Therion...
Items per page:
1 - 10 of 110